Prof. Ching-Yung Lin
CEO, Graphen, Inc
Adjunct Professor, Department of Electrical Engineering and Computer Science at Columbia University.
Biography:
Dr. Ching-Yung Lin founded Graphen, Inc. in 2017 and serves as the CEO. Graphen’s mission is to build a novel whole-brain AI platform to solve challenges in Healthcare, Finance, Automotive, and Energy, and to develop state-of-the-art AI technologies for human well-being. Dr. Lin has also been an Adjunct Professor in the Department of Electrical Engineering and Computer Science at Columbia University since 2005. Graphen is headquartered in New York, with subsidiaries in Taipei, Hong Kong, Singapore, Beijing, and a Tokyo-based representative from the former General Manager of Sony and PanasonicBusiness Development. Company introductions at https://www.graphen.ai
Before founding Graphen, he was IBM Chief Scientist and founded the Network Science and Machine Intelligence Division at the IBM T. J. Watson Research Center. He joined Watson Research in 2000 as a Researcher. Dr. Lin was named an IEEE Fellow in November 2011, the first in the field of Network Science. He is also an adjunct professor at New York University (2014) and the University of Washington(2003-2009).
Inspired by the fact that the human brain is a network of billions of nodes, his research interest has always been artificial intelligence that enables full-brain functions through fundamental R&D breakthroughs. Over the past 20 years, he has led multiple large-scale global AI projects with 30-120 researchers, including 40 from Columbia, CMU, Northeastern University, Northwestern University, UC Berkeley, Stanford Research Institute, etc. The AI Behavior Prediction Project composed of 10 researchers has established a number of AI projects for governments and industries in the United States, the European Union, China, Russia and Southeast Asia. He also led Cognitive Network Research Center including more than 10 universities to study human behavior prediction and brain network. Dr. Lin has also served as the Advisory Committee of the Taiwan‘s bio industrial institution- Development Center of Biotechnology since 2020, helping to promote the development of Taiwan’s AI medical industry.
In addition to the medical field of this talk, Graphen has also made great strides in other fields. In the financial field, Dr. Lin was responsible for the AI financial field during his last two years at IBM, developing its most important applications for the world’s largest financial institutions. He has been invited to speak at the Federal Reserve, the European Central Bank, and the USFINRA on many occasions. He collaborated with the two largest banks in the United States: Chase Bank and Bank of America, the two largest banks in China: Industrial and Commercial Bank of China and Bank of China, the Central Bank of Russia, and other European banks. After the establishment of Graphen, its financial department has established important systems for several banks in China, Hong Kong, New York, and Taiwan, including the central control center of the entire bank, non-performing loan forecast, investment risk analysis, etc. In Taiwan, Graphen Finance’ssystem is deployed in the National CreditCard Center, which handles various anti-money laundering and anti-fraud applications. Graphen Finance’s cryptocurrency anti-money laundering system processes and analyzes the transaction information of more than 150 million users around the world every year, making cryptocurrency behavior transparent, helping to reduce the risk of cryptocurrency and enhancing the possibility of future regulation. In the field of automobiles, Graphen Automotive cooperates with the largest car diagnostic company in the United States to develop AI car doctors, provide maintenance advice and early diagnosis, and cooperate with Taiwanese manufacturers to provide this technology in electric vehicles. In terms of energy, Graphen Energy has established a monitoring system for all of Taipower’s solar panels to predict power generation and detect abnormalities as the basis for future smart grid dispatch.
Dr. Lin has been invited as a keynote speaker at more than 70 conferences, including a co-speaker with the White House Chief Data Scientist at the 2015 American Medical Association Annual Meeting. He has been invited many times to give speeches at the Federal Reserve, the European Central Bank, the USFINRA, the Pentagon, etc. He is the author or co-author of about 200 publications and holds about 50 patents with over 11,000 citations and an h-index of 55 (55 articles have been cited at least 55 times). He is the 2009-10 Chair of the IEEE CAS Multimedia TC and the General Chair of the 2009 IEEE International Multimedia Conference. In 2003, he initiated and led video annotation with 111 researchers at 23 institutes around the world, establishing the first-ever machine learning foundation in the field of computer vision that has driven AI innovation over the past 20 years. Dr. Lin’s work has won 7 Best Paper Awards and has been featured in BusinessWeek magazine 4 times, including a cover story in May 2009. Dr. Lin received his Ph.D. from Columbia University and his MS and BS in Electrical Engineering from National Taiwan University. In 2010, the IBM Career Exploration Review selected Dr.Lin as “a researcher most likely to have the greatest scientific impact on IBM and the world.”
Session Title: Seeing the Dawn of Digital Biology—AI for Drug Development and Precision Health
Abstract:
In the 1972 Nobel Prize winner Christian Anfinsen’s award-winning speech, he expected that one day in the future, humans can directly predict the three dimensional structure of proteins, the constituent units of organisms, from amino acid sequences. After that, the working principles of many organisms and the efficacy of drugs made it easier to understand and predict this scientifically and accurately. Today, 50 years later, AI technology has helped take this step. In December 2021, the Science journal selected the achievement of “using AI technology to successfully predict protein structure” as the biggest scientific achievement of the year, surpassing In Vivo CRISPR, Ancient Soil DNA, COVID 19 Pills, Artificial Antibody, and other inventions.
In this area, in May 2020, the ABI Medical White Paper listed Graphen and Google as two companies that would have a significant impact on drug development. Our goal of establishing Graphen is to build an AI platform with full brain function to improve human well being, especially in biological sciences, to help everyone understand their digital self, and to be able to clearly predict the trend of personal health and diseases in the future. Graphen Medical’s fundamental research utilizes graph computing and quantum physics to predict biological functions at the atomic level. Its self developed Graphen Atom platform provides 12 tools, including protein structure prediction, protein function prediction, protein binding prediction, ADME model prediction, large scale genomic knowledge reasoning and understanding, etc. In this talk, I will describe how we are developing the latest AI technology to help gradually realize this dream of future medicine from the ground up.
Graphen Robotics has recently developed new computer vision and speech based physical robots that replace Lidar and can be used both indoors and outdoors. Its latest Digital Human product realizes the AI virtual human often seen in science fiction films. Lifelike virtual people, with real life interactions and expertise, can help in many labor shortage areas, such as long term care, retail, security, etc., or as a psychological companion. In this talk, I will also introduce our newly developed physical robots, Graphen Adam, and virtual robots, Graphen Ava, which are suitable for many application scenarios of smart hospitals.